A recent study demonstrated that the sGC activator BAY 60–2770 may inhibit the progression from acute kidney injury to chronic kidney disease (CKD), a previously understudied aspect, possibly by improving renal blood flow and tissue oxygenation [49]. This evidence concerns the gene SGCB and chronic kidney disease.